CN111910017A - Multiplex-time PCR (polymerase chain reaction) kit for detecting respiratory pathogens, method and application - Google Patents
Multiplex-time PCR (polymerase chain reaction) kit for detecting respiratory pathogens, method and application Download PDFInfo
- Publication number
- CN111910017A CN111910017A CN202010683147.0A CN202010683147A CN111910017A CN 111910017 A CN111910017 A CN 111910017A CN 202010683147 A CN202010683147 A CN 202010683147A CN 111910017 A CN111910017 A CN 111910017A
- Authority
- CN
- China
- Prior art keywords
- influenza
- virus
- detecting
- probe
- target gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 26
- 244000052769 pathogen Species 0.000 title claims abstract description 19
- 230000000241 respiratory effect Effects 0.000 title claims abstract description 15
- 238000003752 polymerase chain reaction Methods 0.000 title description 6
- 239000000523 sample Substances 0.000 claims abstract description 97
- 238000001514 detection method Methods 0.000 claims abstract description 80
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 53
- 241000430519 Human rhinovirus sp. Species 0.000 claims abstract description 42
- 241000342334 Human metapneumovirus Species 0.000 claims abstract description 41
- 241000712431 Influenza A virus Species 0.000 claims abstract description 40
- 241000713196 Influenza B virus Species 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 239000013641 positive control Substances 0.000 claims abstract description 23
- 239000013642 negative control Substances 0.000 claims abstract description 19
- 238000003753 real-time PCR Methods 0.000 claims abstract description 18
- 102000004190 Enzymes Human genes 0.000 claims abstract description 12
- 108090000790 Enzymes Proteins 0.000 claims abstract description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 11
- 239000011535 reaction buffer Substances 0.000 claims abstract description 11
- 239000000243 solution Substances 0.000 claims abstract description 8
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000010807 real-time PCR kit Methods 0.000 claims abstract description 4
- 230000003321 amplification Effects 0.000 claims description 28
- 238000006243 chemical reaction Methods 0.000 claims description 28
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 28
- 239000013612 plasmid Substances 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 238000004925 denaturation Methods 0.000 claims description 8
- 230000036425 denaturation Effects 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 238000012257 pre-denaturation Methods 0.000 claims description 8
- 238000010839 reverse transcription Methods 0.000 claims description 8
- 230000001717 pathogenic effect Effects 0.000 claims description 7
- 102100034343 Integrase Human genes 0.000 claims description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 6
- 108010006785 Taq Polymerase Proteins 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 239000003161 ribonuclease inhibitor Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 4
- 238000009004 PCR Kit Methods 0.000 claims description 3
- 206010036790 Productive cough Diseases 0.000 claims description 3
- 210000003802 sputum Anatomy 0.000 claims description 3
- 208000024794 sputum Diseases 0.000 claims description 3
- 210000002345 respiratory system Anatomy 0.000 claims description 2
- 208000037797 influenza A Diseases 0.000 claims 1
- 208000037798 influenza B Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 9
- 230000004907 flux Effects 0.000 abstract description 6
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 108020004414 DNA Proteins 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 9
- 244000000010 microbial pathogen Species 0.000 description 8
- 125000006853 reporter group Chemical group 0.000 description 4
- 238000005251 capillar electrophoresis Methods 0.000 description 3
- 238000012136 culture method Methods 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108091093088 Amplicon Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 238000007397 LAMP assay Methods 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Abstract
The invention relates to a multiple real-time PCR kit for detecting respiratory pathogens, a method and application, wherein the kit comprises reagents for detecting influenza A virus, influenza B virus, human rhinovirus and human metapneumovirus, and the reagents comprise a probe for detecting the viruses and a primer pair for specifically amplifying corresponding virus target genes, reaction buffer solution, enzyme mixture, positive control and negative control; the detection channel of the influenza A virus is FAM, the detection channel of the influenza B virus is VIC, the detection channel of the human rhinovirus is Texas Red, and the detection channel of the human metapneumovirus is Cy 5. The kit can detect the four viruses simultaneously, has high sensitivity and specificity, simplifies the operation process, shortens the detection time, improves the detection flux, reduces the detection cost, and can be universally applied to various fluorescent quantitative PCR instruments.
Description
Technical Field
The invention relates to the technical field of biomedicine, in particular to a multiple real-time PCR kit for detecting respiratory pathogens, a method and application thereof.
Background
At present, the clinical diagnosis of respiratory pathogens mainly relies on the traditional separation culture method, and the culture method is the gold standard for clinical pathogen diagnosis, but has certain limitations including: (1) the difficulty of culturing a large number of pathogens is high or the in vitro culture cannot be carried out; (2) the positive rate is low, the false negative rate is high (often more than 50 percent); (3) detection time consumption is as follows: the conventional detection needs 1 to 4 days, and some slow-growing pathogens need 3 to 4 weeks to obtain a culture result; (4) the operation is complicated: high requirements for operators and poor repeatability of results.
In addition to the traditional isolation and culture methods, the detection protocols for respiratory pathogens currently on the market are mostly aimed at nucleic acid detection, and these detection protocols rely on different technical principles. For example: (1) the FilmArray RP panel of Merriepar respectively designs a pair of inner primers and a pair of outer primers aiming at 20 respiratory viruses and bacteria, nucleic acid of a sample is amplified through nested PCR, products are subjected to dissolution curve analysis, and pathogeny is identified according to different dissolution peaks (Tm values) of different products; (2) the multiple detection kit for 13 respiratory pathogens in Haisha firstly performs multiple PCR amplification on sample nucleic acid, then an amplification product is analyzed through capillary electrophoresis, and different pathogens are identified according to the size of a product fragment; (3) the reagent is based on loop-mediated isothermal amplification and chip detection technology, and can be used for rapidly detecting 6 common respiratory viruses. However, although the FilmArray RP panel of Merrieea is simple in operation, rapid and highly automated, it must be implemented only by means of a FilmArray automated analysis platform, and the application range is limited. Although the 13 respiratory pathogens multiple detection kit applied by Haisha can realize one-tube reaction multiple detection, the product can be analyzed by a special capillary electrophoresis apparatus besides a PCR apparatus, the detection period can be prolonged in the capillary electrophoresis analysis process, and the laboratory aerosol pollution is easily caused by uncovering of the amplification product. The detection range of the nucleic acid detection kit for the six respiratory viruses of Boo is narrow, the detection kit can be implemented only by a matched isothermal amplification microfluidic nucleic acid analyzer, and the detection flux is limited by the instrument.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to develop a multiple detection kit capable of identifying a plurality of common respiratory pathogens, aims to ensure high sensitivity and specificity, simultaneously simplifies the operation process, shortens the detection time, improves the detection flux, reduces the detection cost and can be universally applied to a plurality of fluorescent quantitative PCR instruments.
The scheme is based on Real-time PCR (Taqman probe) technology, a pair of specific primers and a Taqman probe are respectively designed for each detection target, the Taqman probe is an oligonucleotide sequence which is complementary with a target sequence and is highly specific, a fluorescence reporter group is marked at the 5 'end of the Taqman probe, a fluorescence quenching group is marked at the 3' end of the Taqman probe, and in the PCR amplification process, when the probe is complete, because the quenching group is close to the reporter group, the fluorescence emitted by the reporter group is absorbed by the quenching group, and no fluorescence signal is emitted; when the primer is extended, the fluorescent probe bound to the template is cleaved by Taq enzyme (5 '→ 3' exonuclease activity), and the reporter group is separated from the quencher group, thereby generating a fluorescent signal. In the multiplex qPCR, each target is amplified by a set of different primers, the specific probe of each target is respectively marked with fluorescent groups in different spectral ranges, a fluorescent quantitative PCR instrument can automatically draw a real-time amplification curve according to a detected fluorescent signal, and finally different amplification products are judged according to the detected fluorescent signal.
The technical scheme adopted by the invention is as follows:
a multiplex-time PCR kit for detecting respiratory pathogens comprises reagents for detecting influenza A viruses, influenza B viruses, human rhinoviruses and human metapneumoviruses.
Further, the reagent comprises a probe for detecting the influenza A virus, a primer pair for specifically amplifying a target gene of the influenza A virus, a probe for detecting the influenza B virus, a primer pair for specifically amplifying a target gene of the influenza B virus, a probe for detecting the human rhinovirus, a primer pair for specifically amplifying a target gene of the human rhinovirus, a probe for detecting the human metapneumovirus and a primer pair for specifically amplifying a target gene of the human metapneumovirus.
Further, the nucleotide FluA-P sequence of the probe for detecting the influenza A virus is shown as SEQ ID NO. 1, and the primer pair FluA-F and FluA-R sequences of the specific amplification influenza A virus target gene are respectively shown as SEQ ID NO. 2 and SEQ ID NO. 3;
the nucleotide FluB-P sequence of the probe for detecting the influenza B virus is shown as SEQ ID NO. 4, and the primer pair FluB-F and FluB-R sequences of the specific amplification influenza B virus target gene are shown as SEQ ID NO. 5 and SEQ ID NO. 6;
the nucleotide HRV-P sequence of the probe for detecting the human rhinovirus is shown as SEQ ID NO. 7, and the sequences of the primer pair HRV-F and HRV-R of the specific amplification human rhinovirus target gene are shown as SEQ ID NO. 8 and SEQ ID NO. 9;
the nucleotide HMPV-P sequence of the probe for detecting the human metapneumovirus is shown as SEQ ID NO. 10, and the primer pair HMPV-F and HMPV-R sequences of the specific amplification human metapneumovirus target gene are shown as SEQ ID NO. 11 and SEQ ID NO. 12;
the gene sequences of SEQ ID NO 1-SEQ ID NO 12 are as follows:
further, the kit also comprises a reaction buffer, an enzyme mixture, a positive control and a negative control.
Further, the reaction buffer comprises MgCl2dNTPs mix, said enzyme Mixture comprisingAMV reverse transcriptase, RNase inhibitor and Taq DNA polymerase, wherein the positive control is a plasmid mixture containing a target gene, and the negative control is Nuclease-free Water (Nuclease-free Water).
Further, MgCl in the reaction buffer2The working concentration of (1) is 2-4mM, the working concentration of dNTPs mix is 350-.
Further, the preparation method of the positive control plasmid mixture containing the target gene comprises the following steps:
4 recombinant plasmids were synthesized by Biotechnology engineering (Shanghai) GmbH, each recombinant plasmid contained 1 amplicon sequence, the vector selected PUC57, and the plasmids were converted to copy number concentrations according to the following conversion formula after concentration quantification:
copies/μL＝(6.02x 10^23)x(ng/μL x 10^-9)/(DNA length x 660)
the pathogenic recombinant plasmids were mixed in equal amounts and diluted with sterile, nuclease-free double distilled water to give a final concentration of 1000 copies of each of the 4 recombinant plasmids.
Further, the detection channel of the influenza a virus is FAM, the detection channel of the influenza b virus is VIC, the detection channel of the human rhinovirus is Texas Red, and the detection channel of the human metapneumovirus is Cy 5.
The kit does not contain a nucleic acid extraction reagent, and the collected clinical sample can be used for detection only after virus nucleic acid extraction and purification.
A method for simultaneously detecting influenza A virus, influenza B virus, human rhinovirus and human metapneumovirus, comprising the steps of:
extracting and purifying microbial nucleic acid from the collected clinical sample to obtain a sample to be detected; detecting a sample to be detected by adopting the multiple real-time PCR kit for detecting the respiratory tract pathogen to obtain detection data; and reading the detection data to obtain a detection result.
Further, the clinical sample includes any one of nasopharyngeal swab, sputum, bronchial lavage and alveolar lavage of a human body.
Further, the kit comprises a probe for detecting the influenza A virus, a primer pair for specifically amplifying a target gene of the influenza A virus, a probe for detecting the influenza B virus, a primer pair for specifically amplifying a target gene of the influenza B virus, a probe for detecting the human rhinovirus, a primer pair for specifically amplifying a target gene of the human rhinovirus, a probe for detecting the human metapneumovirus, a primer pair for specifically amplifying a target gene of the human metapneumovirus, a reaction buffer solution, an enzyme mixture, a positive control and a negative control.
Further, the kit is adopted, the real-time PCR method is utilized to simultaneously detect the influenza A virus, the influenza B virus, the human rhinovirus and the human metapneumovirus in a clinical sample, and the step of obtaining detection data comprises the following steps:
extracting and purifying microbial nucleic acid from the collected clinical sample to obtain a sample to be detected; respectively mixing a sample to be detected, a positive control or a negative control with an equal amount of a probe for detecting influenza A virus, a primer pair for specifically amplifying a target gene of the influenza A virus, a probe for detecting influenza B virus, a primer pair for specifically amplifying a target gene of the influenza B virus, a probe for detecting human rhinovirus, a primer pair for specifically amplifying a target gene of the human rhinovirus, a probe for detecting human metapneumovirus and a primer pair for specifically amplifying a target gene of the human metapneumovirus to respectively obtain a sample mixture to be detected, a positive control mixture and a negative control mixture; detecting the sample mixture to be detected, the positive control mixture and the negative control mixture by using a real-time PCR method to obtain detection data;
preferably, the lowest detection limit of the sample to be detected is 10 copies/reaction;
preferably, the working concentration of the primer pair for specifically amplifying the target gene of the influenza A virus, the primer pair for specifically amplifying the target gene of the influenza B virus, the primer pair for specifically amplifying the target gene of the human rhinovirus and the primer for specifically amplifying the target gene of the human metapneumovirus are all 0.1-1.0 μ M, and more preferably 0.2 μ M;
preferably, the working concentration of the probe for detecting influenza A virus, the probe for detecting influenza B virus, the probe for detecting human rhinovirus and the probe for detecting human metapneumovirus are all 50-250nM, more preferably 100 nM.
Further, the real-time PCR method sequentially comprises three steps of reverse transcription, pre-denaturation, denaturation and extension, wherein the reverse transcription temperature in the reverse transcription step is 45-55 ℃, the reverse transcription time is 10-20min, and the cycle number is 1; the pre-denaturation temperature in the pre-denaturation step is 93-97 ℃, the pre-denaturation time is 25-35s, and the number of cycles is 1; the number of cycles of denaturation and extension is 42-48, wherein the temperature in the denaturation step is 92-98 ℃, the denaturation time is 8-12s, the extension temperature is 55-61 ℃, and the extension time is 30-40 s.
The kit is applied to the real-time PCR method for detecting influenza A virus, influenza B virus, human rhinovirus and human metapneumovirus.
The application is an application for non-diagnostic purposes.
The technical scheme of the invention has the beneficial effects that:
the kit comprises reagents for detecting influenza A virus, influenza B virus, human rhinovirus and human metapneumovirus, wherein the reagents comprise probes for detecting the viruses, primer pairs for specifically amplifying corresponding virus target genes, reaction buffer solution, enzyme mixtures, positive control and negative control; the detection channel of the influenza A virus is FAM, the detection channel of the influenza B virus is VIC, the detection channel of the human rhinovirus is Texas Red, and the detection channel of the human metapneumovirus is Cy 5. The invention judges different amplification products through the fluorescence signals detected by each channel, simplifies the operation process, shortens the detection time, improves the detection flux, reduces the detection cost while having high sensitivity and specificity, and has the advantages of wide detection range, rapidness, convenience, high flux and suitability for the fluorescent quantitative PCR instruments of a plurality of brands/models.
The specific advantages of the invention are illustrated: (1) the detection range comprises a plurality of pathogenic microorganisms common to respiratory tract infection, and the detection range is wider; (2) by adopting a multiple real-time PCR technology, different from product terminal analysis, the amplification process can be observed in real time according to an amplification curve, the whole detection process can be completed within 1.5 hours, and the method is simple and rapid; (3) the Taqman probe is used, so that high specificity of detection can be ensured; (4) products do not need to be uncapped for additional analysis, and the pollution of a laboratory can be reduced as much as possible; (5) the probe marking adopts a channel which is equipped with most of fluorescent quantitative PCR instruments on the market, and is suitable for all fluorescent quantitative PCR instruments such as ABI7500, Shanghai macrosite SLAN-96P, Roche LightCycler480, Bio-Rad CFX96 and the like which are provided with FAM, VIC, Texas Red, Cy5 and Cy3 channels; (6) each tube of reagent is independently packaged, can be freely combined according to different clinical requirements, has high flexibility, can improve the flux to the greatest extent and reduce the cost.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the drawings without creative efforts.
FIG. 1 is a graph showing the amplification curve of the detection result of the kit according to example 1 of the present invention;
FIG. 2 is a graph showing the results of the sensitivity test of the kit according to example 1 of the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the technical solutions of the present invention will be described in detail below. It is to be understood that the described embodiments are merely exemplary of the invention, and not restrictive of the full scope of the invention. All other embodiments, which can be derived by a person skilled in the art from the examples given herein without any inventive step, are within the scope of the present invention.
The sequences of the primers and probes contained in the kit described in the following examples are as follows:
the primer and probe sequences of each pathogenic microorganism are synthesized by the company of Biotechnology engineering (Shanghai) and are stored at-20 ℃ for later use.
The preparation method of the positive control, namely the plasmid mixture containing the target gene, referred to in the following examples comprises:
4 recombinant plasmids were synthesized by Biotechnology engineering (Shanghai) GmbH, each recombinant plasmid contained 1 amplicon sequence, the vector selected PUC57, and the plasmids were converted to copy number concentrations according to the following conversion formula after concentration quantification:
copies/μL＝(6.02x 10^23)x(ng/μL x 10^-9)/(DNA length x 660)
the pathogenic recombinant plasmids were mixed in equal amounts and diluted with sterile, nuclease-free double distilled water to give a final concentration of 1000 copies of recombinant plasmids of 4 pathogenic microorganisms.
Example 1
This example provides a real-time PCR multiplex assay kit for detecting influenza A virus, influenza B virus, human rhinovirus and human metapneumovirus, comprising a probe for detecting influenza A virus and a primer pair for specifically amplifying target gene of influenza A virus, a probe for detecting influenza B virus and a primer pair for specifically amplifying target gene of influenza B virus, a probe for detecting human rhinovirus and a primer pair for specifically amplifying target gene of human rhinovirus, a probe for detecting human metapneumovirus and a primer pair for specifically amplifying target gene of human metapneumovirus, a,MgCl2dNTPs mix, AMV reverse transcriptase, RNase inhibitor, Taq DNA polymerase, plasmid Mixture containing target gene and nuclease-free water;
this example provides a method for detecting bronchial lavage using the above kit:
1. extracting nucleic acid of a clinical sample bronchial lavage fluid, and purifying to obtain a sample to be detected;
2. preparing a reaction system
Thawing the required components in the kit, reversing, uniformly mixing and centrifuging for a short time for later use; mixing primers and probes corresponding to each pathogen with sterile and nuclease-free double distilled water, preparing detection reaction solution according to the following table according to the number of reaction tubes (sample number +2) × 1.1 to be detected,
wherein the final concentration of the primer of each pathogenic microorganism is 0.2 mu M, the final concentration of the probe is 100nM,
wherein, MgCl2The working concentration of (3 mM), the working concentration of dNTPs mix (400. mu. M, AMV), the working concentration of reverse transcriptase (5U/. mu. L, RNA), enzyme inhibitor (40U/. mu.L), and the working concentration of Taq DNA polymerase (5U/. mu.L).
3. Reaction of
Uniformly mixing the prepared reaction system, subpackaging the mixture into optical flat cover PCR reaction tubes according to the amount of 12 mu L, transferring the mixture to a sample processing chamber, adding 8 mu L of samples to be detected into each reaction tube, adding 8 mu L of plasmid mixture containing target genes into a positive control tube, adding 8 mu L of nuclease-free water into a negative control tube, covering the reaction tubes tightly, centrifuging at an instantaneous low speed, and transferring the mixture to a detection area; detecting by using ABI7500, wherein a detection channel of the influenza A virus is FAM, a detection channel of the influenza B virus is VIC, a detection channel of the human rhinovirus is Texas Red, and a detection channel of the human metapneumovirus is Cy 5; putting the reaction tubes into a real-time PCR instrument in sequence, and carrying out amplification reaction according to the following reaction conditions:
and setting the fluorescence internal reference of the instrument as 'None', editing the sample information of each reaction hole according to the operating protocol of the instrument, and selecting a corresponding detection target.
4. Results analysis (with reference to the instrument instructions)
Automatically storing the result after the Analysis is finished, adjusting the Start Value, the End Value and the Threshold Value of Baseline according to the analyzed image (the general Start Value can be 3-15, the End Value can be 5-20, the Value of Threshold is set in a Log map window, so that a Threshold line is positioned in an exponential phase of an amplification curve, the amplification curve of a negative quality control product is straight or lower than the Threshold line), clicking Analysis to automatically obtain the Analysis result, reading the detection result in a Report window, wherein an amplification curve graph is shown in figure 1, when four pathogenic templates exist in a reaction system at the same time, multiple amplification is free of interference, and all signals can be detected;
and (4) judging the standard of the test result: the CT value of each channel detection target of the positive control is less than or equal to 30; the negative control is qualified if the detection target of each channel has no CT value or the CT value is more than 40; the CT value of each detection target in the sample is less than or equal to 40, and the sample is positive, and no CT value or the CT value is more than 40, and the sample is negative;
in the embodiment, the CT value of the influenza A virus is less than or equal to 40, the detection results of the negative control, the influenza B virus, the human rhinovirus and the human metapneumovirus have no CT value, and the CT value of each channel detection target of the positive control is less than or equal to 30.
Example 2
This example is the same as example 1, except that the clinical specimen, the concentrations of primers and probes for amplification of each pathogenic microorganism, the concentrations of system components for amplification reaction, and the conditions for amplification reaction are different from example 1: clinical samples taken in this exampleThe sputum is obtained, the concentration of primers for amplification of each pathogenic microorganism is 0.1 mu M, and the concentration of probes is 50 nM; MgCl in the reaction buffer in the system of the amplification reaction2The working concentration of (2 mM), the working concentration of dNTPs mix is 350. mu.M, the working concentration of AMV reverse transcriptase in the enzyme Mixture is 4U/. mu.L, the working concentration of RNase inhibitor is 35U/. mu.L, the working concentration of Taq DNA polymerase is 4U/. mu.L, and the amplification conditions are shown in the following table:
in the embodiment, the CT value of the influenza B virus is less than or equal to 40, the detection results of the negative control, the influenza A virus, the human rhinovirus and the human metapneumovirus have no CT value, and the CT value of each channel detection target of the positive control is less than or equal to 30.
Example 3
This example is the same as example 1 except that the clinical specimen, the concentrations of primers and probes for amplification of each pathogenic microorganism, the concentrations of components in the amplification reaction system, and the conditions of the amplification reaction are different from example 1: the clinical sample taken in the embodiment is alveolar lavage fluid, the concentration of the primer amplified by each pathogenic microorganism is 1.0 mu M, and the concentration of the probe is 250 nM; MgCl in the reaction buffer2The working concentration of the enzyme Mixture is 4mM, the working concentration of dNTPs mix is 450 mu M respectively, the working concentration of AMV reverse transcriptase in the enzyme Mixture is 6U/mu L, the working concentration of an RNase inhibitor is 45U/mu L, and the working concentration of Taq DNA polymerase is 6U/mu L; amplification conditions are shown in the following table:
in the embodiment, the CT value of the human rhinovirus is less than or equal to 40, the detection results of the negative control, the influenza A virus, the human rhinovirus and the human metapneumovirus have no CT value, and the CT value of each channel detection target of the positive control is less than or equal to 30.
Examples of the experiments
Sensitivity test of the kit described in example 1
The positive control is diluted by 10 times of gradient from high concentration to lower to prepare a series of templates with different concentrations, and the concentrations are as follows: 10^1 copy/mu L, 10^2 copy/mu L, 10^3 copy/mu L, 10^4 copy/mu L, 105 copy/mu L and 106 copy/mu L, a reaction system is prepared according to the method described in the embodiment 1, a reaction template is positive control with 6 gradient concentrations, reaction parameters are set according to corresponding reaction conditions, and result analysis is carried out, specific results are shown in figure 2, template copy numbers corresponding to lines from left to right in the figure are 10^6 copy/mu L, 10^5 copy/mu L, 10^4 copy/mu L, 10^3 copy/mu L, 10^2 copy/mu L and 10^1 copy/mu L in sequence, and the detection lower limit of the method can reach 10 copies/reactions according to the results.
The above description is only for the specific embodiments of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art can easily conceive of the changes or substitutions within the technical scope of the present invention, and all the changes or substitutions should be covered within the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the appended claims.
Sequence listing
<110> Sichuan university Hospital in western China
<120> multiplex-time PCR kit for detecting respiratory pathogens, method and application
<130> 2010
<141> 2020-07-15
<160> 12
<170> SIPOSequenceListing 1.0
<210> 1
<211> 25
<212> DNA
<213> Artificial sequence ()
<400> 1
attttaggat ttgtgttcac gctca 25
<210> 2
<211> 22
<212> DNA
<213> Artificial sequence ()
<400> 2
caagaccaat tttgtcacct ct 22
<210> 3
<211> 20
<212> DNA
<213> Artificial sequence ()
<400> 3
caaatcgtct acgctgcagt 20
<210> 4
<211> 25
<212> DNA
<213> Artificial sequence ()
<400> 4
acttggaacc tcaggatctt gccct 25
<210> 5
<211> 18
<212> DNA
<213> Artificial sequence ()
<400> 5
agcaccagga ggacccta 18
<210> 6
<211> 19
<212> DNA
<213> Artificial sequence ()
<400> 6
gaacagccca agccattgt 19
<210> 7
<211> 25
<212> DNA
<213> Artificial sequence ()
<400> 7
yggctaacct taaccctgya gcyak 25
<210> 8
<211> 17
<212> DNA
<213> Artificial sequence ()
<400> 8
<210> 9
<211> 22
<212> DNA
<213> Artificial sequence ()
<400> 9
aaacacggac acccaaagta gt 22
<210> 10
<211> 24
<212> DNA
<213> Artificial sequence ()
<400> 10
tgggacaagt caaaatgtcr ttcc 24
<210> 11
<211> 25
<212> DNA
<213> Artificial sequence ()
<400> 11
acagtcaaaa tgattatgag taatt 25
<210> 12
<211> 21
<212> DNA
<213> Artificial sequence ()
<400> 12
tgctgcttca ttacccatga a 21
Claims (10)
1. A multiplex-time PCR kit for detecting respiratory pathogens is characterized by comprising reagents for detecting influenza A viruses, influenza B viruses, human rhinoviruses and human metapneumoviruses.
2. The kit of claim 1, wherein the reagents comprise a probe for detecting influenza a virus and a primer pair for specifically amplifying a target gene of influenza a virus, a probe for detecting influenza b virus and a primer pair for specifically amplifying a target gene of influenza b virus, a probe for detecting human rhinovirus and a primer pair for specifically amplifying a target gene of human rhinovirus, a probe for detecting human metapneumovirus and a primer pair for specifically amplifying a target gene of human metapneumovirus.
3. The kit according to claim 2, wherein the nucleotide sequence of the probe for detecting influenza A virus is shown as SEQ ID NO. 1, and the sequences of the primer pair for specifically amplifying the target gene of influenza A virus are shown as SEQ ID NO. 2 and SEQ ID NO. 3;
the nucleotide sequence of the probe for detecting the influenza B virus is shown as SEQ ID NO. 4, and the primer pair sequence of the specific amplification influenza B virus target gene is shown as SEQ ID NO. 5 and SEQ ID NO. 6;
the nucleotide sequence of the probe for detecting the human rhinovirus is shown as SEQ ID NO. 7, and the sequence of the primer pair for specifically amplifying the human rhinovirus target gene is shown as SEQ ID NO. 8 and SEQ ID NO. 9;
the nucleotide sequence of the probe for detecting the human metapneumovirus is shown as SEQ ID NO. 10, and the sequences of the primer pair for specifically amplifying the human metapneumovirus target gene are shown as SEQ ID NO. 11 and SEQ ID NO. 12.
4. The kit of claim 1, further comprising a reaction buffer, an enzyme mixture, a positive control, and a negative control.
5. The kit according to claim 4, characterized in that the reaction buffer comprises MgCl2dNTPs mix, the enzyme Mixture comprises AMV reverse transcriptase, RNase inhibitor and Taq DNA polymerase, the positive control is a plasmid Mixture containing a target gene, and the negative control is nuclease-free water.
6. The kit according to claim 1, wherein the detection channel for influenza a virus is FAM, the detection channel for influenza b virus is VIC, the detection channel for human rhinovirus is Texas Red, and the detection channel for human metapneumovirus is Cy 5.
7. A method for simultaneously detecting influenza A virus, influenza B virus, human rhinovirus and human metapneumovirus is characterized by comprising the following steps:
extracting and purifying microbial nucleic acid from the collected clinical sample to obtain a sample to be detected; detecting a sample to be detected by adopting the multiple real-time PCR kit for detecting the respiratory tract pathogen to obtain detection data; and reading the detection data to obtain a detection result.
8. The method of claim 7, wherein the clinical sample comprises any one of a nasopharyngeal swab, sputum, bronchial lavage, and alveolar lavage of a human; the kit comprises a probe for detecting the influenza A virus, a primer pair for specifically amplifying a target gene of the influenza A virus, a probe for detecting the influenza B virus, a primer pair for specifically amplifying a target gene of the influenza B virus, a probe for detecting the human rhinovirus, a primer pair for specifically amplifying a target gene of the human rhinovirus, a probe for detecting the human metapneumovirus, a primer pair for specifically amplifying a target gene of the human metapneumovirus, a reaction buffer solution, an enzyme mixture, a positive control and a negative control; by adopting the kit, the real-time PCR method is utilized to simultaneously detect the influenza A virus, the influenza B virus, the human rhinovirus and the human metapneumovirus in a clinical sample, and the step of obtaining detection data comprises the following steps:
extracting and purifying microbial nucleic acid from the collected clinical sample to obtain a sample to be detected; respectively mixing a sample to be detected, a positive control or a negative control with an equal amount of a probe for detecting influenza A virus, a primer pair for specifically amplifying a target gene of the influenza A virus, a probe for detecting influenza B virus, a primer pair for specifically amplifying a target gene of the influenza B virus, a probe for detecting human rhinovirus, a primer pair for specifically amplifying a target gene of the human rhinovirus, a probe for detecting human metapneumovirus and a primer pair for specifically amplifying a target gene of the human metapneumovirus to respectively obtain a sample mixture to be detected, a positive control mixture and a negative control mixture; detecting the sample mixture to be detected, the positive control mixture and the negative control mixture by using a real-time PCR method to obtain detection data;
preferably, the lowest detection limit of the sample to be detected is 10 copies/reaction;
preferably, the working concentration of the primer pair for specifically amplifying the target gene of the influenza A virus, the primer pair for specifically amplifying the target gene of the influenza B virus, the primer pair for specifically amplifying the target gene of the human rhinovirus and the primer for specifically amplifying the target gene of the human metapneumovirus are all 0.1-1.0 μ M, and more preferably 0.2 μ M;
preferably, the working concentration of the probe for detecting influenza A virus, the probe for detecting influenza B virus, the probe for detecting human rhinovirus and the probe for detecting human metapneumovirus are all 50-250nM, more preferably 100 nM.
9. The detection method according to claim 7, wherein the real-time PCR method comprises three steps of reverse transcription, pre-denaturation, denaturation and extension in sequence, wherein the reverse transcription temperature in the reverse transcription step is 45-55 ℃, the reverse transcription time is 10-20min, and the cycle number is 1; the pre-denaturation temperature in the pre-denaturation step is 93-97 ℃, the pre-denaturation time is 25-35s, and the number of cycles is 1; the number of cycles of denaturation and extension is 42-48, wherein the temperature in the denaturation step is 92-98 ℃, the denaturation time is 8-12s, the extension temperature is 55-61 ℃, and the extension time is 30-40 s.
10. Use of the kit of any one of claims 1 to 6 for the real-time PCR detection of influenza A, influenza B, human rhinovirus and human metapneumovirus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010683147.0A CN111910017A (en) | 2020-07-15 | 2020-07-15 | Multiplex-time PCR (polymerase chain reaction) kit for detecting respiratory pathogens, method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010683147.0A CN111910017A (en) | 2020-07-15 | 2020-07-15 | Multiplex-time PCR (polymerase chain reaction) kit for detecting respiratory pathogens, method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111910017A true CN111910017A (en) | 2020-11-10 |
Family
ID=73280149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010683147.0A Pending CN111910017A (en) | 2020-07-15 | 2020-07-15 | Multiplex-time PCR (polymerase chain reaction) kit for detecting respiratory pathogens, method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111910017A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113186348A (en) * | 2021-05-21 | 2021-07-30 | 广东科蓝生物技术有限公司 | Primer combination and method for detecting common respiratory viruses |
| CN113621735A (en) * | 2021-08-11 | 2021-11-09 | 江苏金迪克生物技术股份有限公司 | Method for detecting influenza virus titer by fluorescent quantitative PCR |
| CN113943836A (en) * | 2021-11-16 | 2022-01-18 | 圣湘生物科技股份有限公司 | Compositions, kits, methods and uses for detecting pathogens causing respiratory tract infections and identifying pathogen species |
| CN114058742A (en) * | 2022-01-18 | 2022-02-18 | 广州科方生物技术股份有限公司 | Primer probe composition, kit containing same and detection method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109609692A (en) * | 2018-12-25 | 2019-04-12 | 北京卓诚惠生生物科技股份有限公司 | For detecting the nucleic acid reagent, kit, system and method for respiratory tract infection pathogen |
-
2020
- 2020-07-15 CN CN202010683147.0A patent/CN111910017A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109609692A (en) * | 2018-12-25 | 2019-04-12 | 北京卓诚惠生生物科技股份有限公司 | For detecting the nucleic acid reagent, kit, system and method for respiratory tract infection pathogen |
Non-Patent Citations (2)
| Title |
|---|
| 严菊英等: ""乙型流行性感冒病毒的基因快速检测", 《中国卫生检验杂志》 * |
| 刘师文等: ""江西省2438 例急性呼吸道感染儿童中人偏肺病毒感染分析"", 《实验与检验科学》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113186348A (en) * | 2021-05-21 | 2021-07-30 | 广东科蓝生物技术有限公司 | Primer combination and method for detecting common respiratory viruses |
| CN113621735A (en) * | 2021-08-11 | 2021-11-09 | 江苏金迪克生物技术股份有限公司 | Method for detecting influenza virus titer by fluorescent quantitative PCR |
| CN113943836A (en) * | 2021-11-16 | 2022-01-18 | 圣湘生物科技股份有限公司 | Compositions, kits, methods and uses for detecting pathogens causing respiratory tract infections and identifying pathogen species |
| CN113943836B (en) * | 2021-11-16 | 2023-09-22 | 圣湘生物科技股份有限公司 | Compositions, kits, methods and uses for detecting pathogens causing respiratory tract infections and identifying pathogen species |
| CN114058742A (en) * | 2022-01-18 | 2022-02-18 | 广州科方生物技术股份有限公司 | Primer probe composition, kit containing same and detection method thereof |
| CN114058742B (en) * | 2022-01-18 | 2022-04-22 | 广州科方生物技术股份有限公司 | Primer probe composition, kit containing same and detection method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4202064A1 (en) | Kit and method for isothermal rapid detection of sars-cov-2 virus nucleic acid | |
| CN111910017A (en) | Multiplex-time PCR (polymerase chain reaction) kit for detecting respiratory pathogens, method and application | |
| CN113817868B (en) | Primer, probe composition and kit for detecting novel coronavirus and variant strain thereof | |
| CN111926114B (en) | Multiplex real-time PCR kit, method and application for detecting parainfluenza virus | |
| CN107245531B (en) | Diarrhea pathogen multiple gene detection system and kit and application thereof | |
| WO2022089550A1 (en) | Novel compositions and methods for coronavirus detection | |
| CN110408725B (en) | Kit for multiple detection of respiratory pathogens | |
| CN111893215A (en) | Multiplex-time PCR kit for detecting coronavirus, method and application | |
| WO2023109032A1 (en) | Multiple nucleic acid detection system, and preparation method therefor and use thereof | |
| CN110273026B (en) | Multiple detection kit and detection method for respiratory tract infection | |
| CN110331232B (en) | Multiple nucleic acid detection kit for respiratory pathogens | |
| CN107083446B (en) | Diarrhea pathogenic bacteria multiple gene detection system and kit and application thereof | |
| CN110904198A (en) | Nucleic acid one-step detection method based on constant-temperature amplification and gene editing | |
| CN110938711A (en) | Real-time fluorescent RAA primer, probe and kit for detecting avian infectious laryngotracheitis virus and using method of real-time fluorescent RAA primer, probe and kit | |
| CN110607381B (en) | Mycobacterium tuberculosis detection kit and method | |
| CN105755134B (en) | Endonuclease-mediated real-time multiple cross-displacement nucleic acid amplification technology and application | |
| CN112301152A (en) | Multiple fluorescence RDA method and kit for rapidly detecting porcine pseudorabies virus, porcine circovirus and porcine parvovirus | |
| CN115029345A (en) | Nucleic acid detection kit based on CRISPR and application thereof | |
| CN112899385A (en) | Primer group and probe for identifying Brucella S2 vaccine strain and wild strain and application of primer group and probe | |
| CN111944923B (en) | Multiplex fluorescence PCR kit, method and application for detecting respiratory pathogens | |
| EP3885455A1 (en) | Method and kit for the detection of sars-cov-2 virus in a sample based on reverse transcription loop-mediated isothermal amplification (rt-lamp) | |
| CN111893197B (en) | Multiplex fluorescence PCR (polymerase chain reaction) kit and method for detecting common respiratory bacteria | |
| CN115125330A (en) | Detection kit for detecting different variants of novel coronavirus and application thereof | |
| CN116219071B (en) | Multiplex qPCR kit for simultaneously detecting and identifying type I, type IIa and type IIb monkey poxviruses | |
| WO2023236037A1 (en) | Hpv nucleic acid detection kit, and preparation method therefor and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201110 |